Targeting malignant glioma survival signalling to improve clinical outcomes

Journal of Clinical Neuroscience

Volumn 14, Issue 4, 2007, Pages 301-308

  Wong, Michael L H ^a   Kaye, Andrew H ^a   Hovens, Christopher M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antineoplastic agents; Glioma therapy; Proto oncogene proteins c akt; Ras protein

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AP 23573; BEVACIZUMAB; BORTEZOMIB; CELL SURFACE RECEPTOR; CETUXIMAB; CYTOTOXIC AGENT; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GROWTH FACTOR; IMATINIB; LAPATINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; PAZOPANIB; PF 00299804; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

APOPTOSIS; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GLIOBLASTOMA; GLIOMA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ADULT; BRAIN NEOPLASMS; CELL SURVIVAL; DRUG DESIGN; GLIOMA; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 33847359256     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2006.11.005     Document Type: Review

References (105)

1. Legler J.M., Ries L.A., Smith M.A., et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91 (1999) 1382-1390
2. Kowalczuk A., Macdonald R.L., Amidei C., et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41 (1997) 1028-1036 discussion 1036-1038
3. Ruben J.D., Dally M., Bailey M., et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 499-508
4. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
5. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
6. Stylli S.S., Howes M., MacGregor L., et al. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci 11 (2004) 584-596
7. Stylli S.S., and Kaye A.H. Photodynamic therapy of cerebral glioma: A review Part I - a biological basis. J Clin Neurosci 13 (2006) 615-625
8. Stylli S.S., and Kaye A.H. Photodynamic therapy of cerebral glioma: A review Part II - Clinical studies. J Clin Neurosci 13 (2006) 709-717
9. Stylli S.S., Kaye A.H., MacGregor L., et al. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 12 (2005) 389-398
10. Diehl J.A., Cheng M., Roussel M.F., et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12 (1998) 3499-3511
11. Nave B.T., Ouwens M., Withers D.J., et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344 (1999) 427-431
12. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
13. Novak U., and Kaye A.H. Extracellular matrix and the brain: components and function. J Clin Neurosci 7 (2000) 280-290
14. Tsatas D., Kanagasundaram V., Kaye A., et al. EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci 9 (2002) 282-288
15. Tsatas D., and Kaye A.H. The role of the plasminogen activation cascade in glioma cell invasion: a review. J Clin Neurosci 10 (2003) 139-145
16. Morokoff A.P., and Novak U. Targeted therapy for malignant gliomas. J Clin Neurosci 11 (2004) 807-818
17. Goldman J.M., and Melo J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1084-1086
18. Baselga J., and Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 4 (2002) 317-324
19. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 353 (1998) 583-605
20. Wells A. EGF receptor. Int J Biochem Cell Biol 31 (1999) 637-643
21. Soni D., King J.A., Kaye A.H., et al. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J Clin Neurosci 12 (2005) 1-5
22. Libermann T.A., Nusbaum H.R., Razon N., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 (1985) 144-147
23. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52 (1992) 3213-3219
24. Berkman R.A., Merrill M.J., Reinhold W.C., et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91 (1993) 153-159
25. Guha A., Dashner K., Black P.M., et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60 (1995) 168-173
26. Fruman D.A., Meyers R.E., and Cantley L.C. Phosphoinositide kinases. Annu Rev Biochem 67 (1998) 481-507
27. Yu J., Zhang Y., McIlroy J., et al. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18 (1998) 1379-1387
28. Kodaki T., Woscholski R., Hallberg B., et al. The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 4 (1994) 798-806
29. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 (1998) 13375-13378
30. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
31. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
32. Andjelkovic M., Alessi D.R., Meier R., et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 272 (1997) 31515-31524
33. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 (2000) 561-576
34. Alessi D.R., James S.R., Downes C.P., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7 (1997) 261-269
35. Partovian C., and Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 16 (2004) 951-957
36. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
37. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
38. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
39. Zhou B.P., Liao Y., Xia W., et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3 (2001) 973-982
40. Ermoian P., Furniss C.S., Lamborn K.R., et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8 (2002) 1100-1106
41. Jones R.G., Parsons M., Bonnard M., et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 191 (2000) 1721-1734
42. Bernal-Mizrachi E., Wen W., Stahlhut S., et al. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108 (2001) 1631-1638
43. Hutchinson J., Jin J., Cardiff R.D., et al. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21 (2001) 2203-2212
44. Holland E.C., Celestino J., Dai C., et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25 (2000) 55-57
45. Buday L., and Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73 (1993) 611-620
46. Kato K., Cox A.D., Hisaka M.M., et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89 (1992) 6403-6407
47. Sun J., Qian Y., Hamilton A.D., et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16 (1998) 1467-1473
48. Moodie S.A., Willumsen B.M., Weber M.J., et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260 (1993) 1658-1661
49. Pathan N.I., Ashendel C.L., Geahlen R.L., et al. Activation of T cell Raf-1 at mitosis requires the protein-tyrosine kinase Lck. J Biol Chem 271 (1996) 30315-30317
50. Sozeri O., Vollmer K., Liyanage M., et al. Activation of the c-Raf protein kinase by protein kinase C phosphorylation. Oncogene 7 (1992) 2259-2262
51. Papin C., Eychene A., Brunet A., et al. B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. Oncogene 10 (1995) 1647-1651
52. Zheng C.F., and Guan K.L. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem 268 (1993) 23933-23939
53. Khokhlatchev A.V., Canagarajah B., Wilsbacher J., et al. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93 (1998) 605-615
54. Shapiro P.S., Whalen A.M., Tolwinski N.S., et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 19 (1999) 3551-3560
55. Sturgill T.W., Ray L.B., Erikson E., et al. Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334 (1988) 715-718
56. Xing J., Ginty D., and Greenberg M.E. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273 (1996) 959-963
57. Joel P.B., Smith J., Sturgill T.W., et al. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18 (1998) 1978-1984
58. Schouten G.J., Vertegaal A.C., Whiteside S.T., et al. IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J 16 (1997) 3133-3144
59. Chen R.H., Abate C., and Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90 (1993) 10952-10956
60. Pardridge W.M. Molecular biology of the blood-brain barrier. Methods Mol Med 89 (2003) 385-399
61. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
62. Rich J.N., and Bigner D.D. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3 (2004) 430-446
63. Kenney J., Schmiedl U., Maravilla K., et al. Measurement of blood-brain barrier permeability in a tumor model using magnetic resonance imaging with gadolinium-DTPA. Magn Reson Med 27 (1992) 68-75
64. Zagzag D., Brem S., and Robert F. Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131 (1988) 361-372
65. van Vulpen M., Kal H.B., Taphoorn M.J., et al. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep 9 (2002) 683-688
66. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J Clin Oncol 24 18S (2006) 1506
67. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66 (2006) 1258-1260
68. Sadones J., Chaskis C., Joosens E.J., et al. A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. J Clin Oncol 24 18S (2006) 1558
69. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593
70. Wen P.Y., Yung W.K.A., Lamborn K., et al. Phase I/II study of imatiinib mesylate (STI571) for patients with recurrent malignany gliomas (NABTC 99-08). Neuro-oncol 6 (2004) 385
71. van den Bent M., Brandes A.A., van Oosterom A., et al. Multicentre phase II study of imatinib mesylate (Gleevec) in patients with recurrent glioblastoma: An EORTC NDDG/BTG intergroup study. Neuro-oncol 6 (2004) 383
72. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
73. Cloughesy T., Yung A., Vrendenberg J., et al. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome. J Clin Oncol 23 16S (2005) 1507
74. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 (1999) 2572-2578
75. Senior K. Gleevec does not cross blood-brain barrier. Lancet Oncol 4 (2003) 198
76. Heimberger A.B., Learn C.A., Archer G.E., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 8 (2002) 3496-3502
77. Fleming T.P., Saxena A., Clark W.C., et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52 (1992) 4550-4553
78. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23 (2005) 9359-9368
79. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16 (2005) 1702-1708
80. Prados M.D., Larson D.A., Lamborn K., et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40 (1998) 57-63
81. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12 (2006) 860-868
82. Doherty L., Gigas D.C., Kesari S., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 (2006) 156-158
83. Brewer C.J., Suh J.H., Stevens G.H.J., et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme. J Clin Oncol 23 16S (2005) 1567
84. Adnane L., Trail P.A., Taylor I., et al. Sorafenib (BAY 43-9006, Nexavar)), a Dual-Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods Enzymol 407 (2005) 597-612
85. Serkova N., Jacobsen W., Niemann C.U., et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 133 (2001) 875-885
86. Kwon C.H., Zhu X., Zhang J., et al. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA 100 (2003) 12923-12928
87. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
88. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
89. Nguyen T.D., Lassman A.B., Lis E., et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 24 (2006) 1507
90. Robertson J.F. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 30 (2004) 695-706
91. Ramachandran C., Khatib Z., Petkarou A., et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol 67 (2004) 19-28
92. Aeder S.E., Martin P.M., Soh J.W., et al. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23 (2004) 9062-9069
93. Couldwell W.T., Hinton D.R., Surnock A.A., et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 2 (1996) 619-622
94. Tang P., Roldan G., Brasher P.M., et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78 (2006) 311-316
95. Brada M., Hoang-Xuan K., Rampling R., et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 (2001) 259-266
96. Graff J.R., McNulty A.M., Hanna K.R., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
97. Sebti S.M., and Hamilton A.D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19 (2000) 6584-6593
98. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24 (2006) 3651-3656
99. Gilbert M.R., Gaupp P., Liu V., et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J Clin Oncol 24 18S (2006) 1556
100. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99 (2002) 14374-14379
101. David E., Sun S.Y., Waller E.K., et al. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106 (2005) 4322-4329
102. Phuphanich S., Supko J., Carson K.A., et al. Phase I trial of bortezomib in adults with recurrent malignant glioma. J Clin Oncol 24 18S (2006) 1567
103. Mendelsohn J., and Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89 (1997) 341-343
104. Li B., Chang C.M., Yuan M., et al. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63 (2003) 7443-7450
105. She Q.B., Solit D., Bass A., et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9 (2003) 4340-4346